



Statin Therapy for Patients with Cardiovascular Disease (SPC)

HEDIS® Measurement Year 2024

Measure Description: Assesses the percentage of males 21-75 years of age and females 40-75 years of age during the measurement year, who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. The following rates are reported:

- Received Statin Therapy: Members who were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year.
- Statin Adherence 80%: Members who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period.

Eligible Population

Males 21-75 years of age and females 40-75 years of age who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD).

Product Lines

Commercial, Medicaid, Medicare

Data Collection Method

Administrative (claims), Supplemental data

Exclusions

Members are excluded from the measure if they meet the following criteria:

- Members who are in hospice or receiving palliative care.
- Members 66 years of age and older as of December 31 of the measurement year with a frailty and advanced illness diagnosis during the measurement year.
- Members diagnosed with myalgia, myositis, myopathy, or rhabdomyolysis.
- Members diagnosed with cirrhosis, dialysis, ESRD, or pregnancy.

Measure Compliance (numerator)

Adherence is determined by the member being prescribed and remaining on their high or moderate-intensity statin medications for 80% of their treatment period. This is determined by pharmacy claims data. Two rates are reported:

Numerator 1 – Received Statin Therapy

The number of members who had at least one dispensing event for a high-intensity or moderate-intensity statin medication.

Numerator 2 – Statin Adherence 80%

The number of members who had at least one dispensing event for a high-intensity or moderate-intensity statin medication and remained on the medication for at least 80% of their treatment period.



Statin Therapy for Patients with Cardiovascular Disease (SPC)

HEDIS® Measurement Year 2024

Measure Compliance (numerator), continued

The medications NCQA lists in the HEDIS specifications are below. This is a general list and should not replace the advice or care you provide your patients regarding what is optimal to meet their healthcare needs.

High and Moderate-Intensity Statin Medications

Description	Prescription
High-Intensity Statin Therapy	Atorvastatin 40-80 mg Amlodipine-atorvastatin 40-80 mg Rosuvastatin 20-40 mg Simvastatin 80 mg Ezetimibe-simvastatin 80 mg
Moderate-Intensity Statin Therapy	Atorvastatin 10-20 mg Amlodipine-atorvastatin 10-20 mg Rosuvastatin 5-10 mg Simvastatin 20-40 mg Ezetimibe-simvastatin 20-40 mg Pravastatin 40-80 mg Lovastatin 40 mg Pitavastatin 1-4 mg Fluvastatin 40-80 mg

For questions, please contact your practice management consultant. To identify your practice management consultant please refer to <https://healthplan.org/providers/overview/meet-practice-management-consultant>.

The Health Plan has a team of member advocates, health coaches, social workers and nurses who can assist you and your patients to remove or overcome any barriers to care through benefit assistance, community resource referrals or enrollment in a THP clinical program. To refer a patient who is a THP member for assistance, call **1.877.903.7504** and let us know what we can do to help your patient receive and adhere to your recommended plan of care.